299 related articles for article (PubMed ID: 28923104)
1. Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection.
Garcia-Carbonero R; Salazar R; Duran I; Osman-Garcia I; Paz-Ares L; Bozada JM; Boni V; Blanc C; Seymour L; Beadle J; Alvis S; Champion B; Calvo E; Fisher K
J Immunother Cancer; 2017 Sep; 5(1):71. PubMed ID: 28923104
[TBL] [Abstract][Full Text] [Related]
2. A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE).
Machiels JP; Salazar R; Rottey S; Duran I; Dirix L; Geboes K; Wilkinson-Blanc C; Pover G; Alvis S; Champion B; Fisher K; McElwaine-Johnn H; Beadle J; Calvo E
J Immunother Cancer; 2019 Jan; 7(1):20. PubMed ID: 30691536
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced/metastatic epithelial cancer: a phase I clinical trial (SPICE).
Fakih M; Harb W; Mahadevan D; Babiker H; Berlin J; Lillie T; Krige D; Carter J; Cox C; Patel M; Parfitt L; Powell M; Rosen L
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37094988
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial.
Moreno V; Barretina-Ginesta MP; García-Donas J; Jayson GC; Roxburgh P; Vázquez RM; Michael A; Antón-Torres A; Brown R; Krige D; Champion B; McNeish I
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34893524
[TBL] [Abstract][Full Text] [Related]
5. Group B adenovirus enadenotucirev infects polarised colorectal cancer cells efficiently from the basolateral surface expected to be encountered during intravenous delivery to treat disseminated cancer.
Chia SL; Lei J; Ferguson DJP; Dyer A; Fisher KD; Seymour LW
Virology; 2017 May; 505():162-171. PubMed ID: 28260622
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus.
Illingworth S; Di Y; Bauzon M; Lei J; Duffy MR; Alvis S; Champion B; Lieber A; Hermiston T; Seymour LW; Beadle J; Fisher K
Mol Ther Oncolytics; 2017 Jun; 5():62-74. PubMed ID: 28480328
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
[TBL] [Abstract][Full Text] [Related]
8. Phase I Trial of Intratumoral Injection of
Lee JM; Lee MH; Garon E; Goldman JW; Salehi-Rad R; Baratelli FE; Schaue D; Wang G; Rosen F; Yanagawa J; Walser TC; Lin Y; Park SJ; Adams S; Marincola FM; Tumeh PC; Abtin F; Suh R; Reckamp KL; Lee G; Wallace WD; Lee S; Zeng G; Elashoff DA; Sharma S; Dubinett SM
Clin Cancer Res; 2017 Aug; 23(16):4556-4568. PubMed ID: 28468947
[No Abstract] [Full Text] [Related]
9. Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial.
Dickhoff C; Senan S; Schneiders FL; Veltman J; Hashemi S; Daniels JMA; Fransen M; Heineman DJ; Radonic T; van de Ven PM; Bartelink IH; Meijboom LJ; Garcia-Vallejo JJ; Oprea-Lager DE; de Gruijl TD; Bahce I
BMC Cancer; 2020 Aug; 20(1):764. PubMed ID: 32795284
[TBL] [Abstract][Full Text] [Related]
10. Anti-PD-1/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis.
Park R; Lopes L; Saeed A
Clin Transl Oncol; 2021 Jan; 23(1):100-109. PubMed ID: 32495269
[TBL] [Abstract][Full Text] [Related]
11. Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus.
Bazan-Peregrino M; Carlisle RC; Hernandez-Alcoceba R; Iggo R; Homicsko K; Fisher KD; Halldén G; Mautner V; Shen Y; Seymour LW
Hum Gene Ther; 2008 Sep; 19(9):873-86. PubMed ID: 18710328
[TBL] [Abstract][Full Text] [Related]
12. Antitumor virotherapy using syngeneic or allogeneic mesenchymal stem cell carriers induces systemic immune response and intratumoral leukocyte infiltration in mice.
Morales-Molina Á; Gambera S; Cejalvo T; Moreno R; Rodríguez-Milla MÁ; Perisé-Barrios AJ; García-Castro J
Cancer Immunol Immunother; 2018 Oct; 67(10):1589-1602. PubMed ID: 30066102
[TBL] [Abstract][Full Text] [Related]
13. An Oncolytic Adenovirus Encoding Decorin and Granulocyte Macrophage Colony Stimulating Factor Inhibits Tumor Growth in a Colorectal Tumor Model by Targeting Pro-Tumorigenic Signals and via Immune Activation.
Liu Z; Yang Y; Zhang X; Wang H; Xu W; Wang H; Xiao F; Bai Z; Yao H; Ma X; Jin L; Wu C; Seth P; Zhang Z; Wang L
Hum Gene Ther; 2017 Aug; 28(8):667-680. PubMed ID: 28530155
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Gene-Mediated Cytotoxic Immunotherapy for Non-Small-Cell Lung Cancer: Safety and Immunologic Activity.
Predina JD; Haas AR; Martinez M; O'Brien S; Moon EK; Woodruff P; Stadanlick J; Corbett C; Frenzel-Sulyok L; Bryski MG; Eruslanov E; Deshpande C; Langer C; Aguilar LK; Guzik BW; Manzanera AG; Aguilar-Cordova E; Singhal S; Albelda SM
Mol Ther; 2021 Feb; 29(2):658-670. PubMed ID: 33160076
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
Shu CA; Gainor JF; Awad MM; Chiuzan C; Grigg CM; Pabani A; Garofano RF; Stoopler MB; Cheng SK; White A; Lanuti M; D'Ovidio F; Bacchetta M; Sonett JR; Saqi A; Rizvi NA
Lancet Oncol; 2020 Jun; 21(6):786-795. PubMed ID: 32386568
[TBL] [Abstract][Full Text] [Related]
16. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
17. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints.
Reid T; Galanis E; Abbruzzese J; Sze D; Wein LM; Andrews J; Randlev B; Heise C; Uprichard M; Hatfield M; Rome L; Rubin J; Kirn D
Cancer Res; 2002 Nov; 62(21):6070-9. PubMed ID: 12414631
[TBL] [Abstract][Full Text] [Related]
18. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer.
Nemunaitis J; Swisher SG; Timmons T; Connors D; Mack M; Doerksen L; Weill D; Wait J; Lawrence DD; Kemp BL; Fossella F; Glisson BS; Hong WK; Khuri FR; Kurie JM; Lee JJ; Lee JS; Nguyen DM; Nesbitt JC; Perez-Soler R; Pisters KM; Putnam JB; Richli WR; Shin DM; Walsh GL; Merritt J; Roth J
J Clin Oncol; 2000 Feb; 18(3):609-22. PubMed ID: 10653876
[TBL] [Abstract][Full Text] [Related]
19. Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer.
Papachristofilou A; Hipp MM; Klinkhardt U; Früh M; Sebastian M; Weiss C; Pless M; Cathomas R; Hilbe W; Pall G; Wehler T; Alt J; Bischoff H; Geißler M; Griesinger F; Kallen KJ; Fotin-Mleczek M; Schröder A; Scheel B; Muth A; Seibel T; Stosnach C; Doener F; Hong HS; Koch SD; Gnad-Vogt U; Zippelius A
J Immunother Cancer; 2019 Feb; 7(1):38. PubMed ID: 30736848
[TBL] [Abstract][Full Text] [Related]
20. Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.
Patel MR; Jacobson BA; Ji Y; Drees J; Tang S; Xiong K; Wang H; Prigge JE; Dash AS; Kratzke AK; Mesev E; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA
Oncotarget; 2015 Oct; 6(32):33165-77. PubMed ID: 26431376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
